1st Patient Dosed in Phase 2 Trial of Investigational PTG-200 for Crohn’s Disease, Protagonist Announces
News
The first patient has been dosed in Protagonist Therapeutics’ Phase 2 clinical trial of PTG-200 for the treatment of moderate to severe Crohn’s disease, the company announced. Still recruiting at ... Read more